To analyze the impact of the number of cycles of collagenase Clostridium histolyticum (CCH) intralesional injection therapy on outcomes in order to further characterize CCH therapy.
We conducted a retrospective review of the records of all patients treated with CCH for PD between 04/2014 and 03/2016. Collected variables included demographics, pre- and post-treatment sexual function, penile curvature, penile vascular findings, and treatment outcomes.
A total of 77 patients were included in the study, of which 41 (53%) completed four cycles of treatment, consisting of eight total injections. For all-comers regardless of numbers of cycles, curvature improved from 58.2° (SD=17.9°, range=30-105°) pre-treatment to 41.0 degrees (SD=17.0°, range=0-85°) post-treatment (p<0.001). In a repeated measures model, penile curvature improved significantly following the first three cycles, but not the fourth. Patients who had a ≥20% final reduction in curvature had a significantly greater change in curvature following the first injection (-16.2 degrees vs. -5.8 degrees, p<0.001).
Intralesional CCH therapy is an effective minimally invasive treatment for PD, although the therapeutic benefit may decline after the third cycle of treatment. Patients with ≥20% reduction in curvature at the conclusion of treatment documented a greater curvature improvement after the first cycle and received more cycles of CCH.
Urology. 2016 Nov 02 [Epub ahead of print]
James Anaissie, Faysal A Yafi, Kenneth J DeLay, Elizabeth J Traore, Suresh C Sikka, Wayne J G Hellstrom
Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA., Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: .